Peringatan Keamanan

No data available.

Desirudin

DB11095

biotech approved

Deskripsi

Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52.

It is mainly indicated for the prevention of deep vein thrombosis in hip replacement surgery patients.
Common side effects include: Bleeding gums, collection of blood under the skin, coughing up blood, deep, dark purple bruise and difficulty with breathing or swallowing.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) ~2 hours.
Volume Distribusi 0.25 L/kg.
Klirens (Clearance) 1.5 to 2.7 mL/min/kg.

Absorpsi

Absorption is complete after subcutaneous administration. Time to peak in plasma is 1 to 3 hours.

Metabolisme

Human and animal data suggest that desirudin is primarily eliminated and metabolized by the kidney. The total urinary excretion of unchanged desirudin amounts to 40 to 50% of the administered dose. Metabolites lacking one or two C-terminal amino acids constitute a minor proportion of the material recovered from urine (< 7%). There is no evidence for the presence of other metabolites. This indicates that desirudin is metabolized by stepwise degradation from the C-terminus probably catalyzed by carboxypeptidase(s) such as carboxypeptidase A.

Rute Eliminasi

Urine (40% to 50% as unchanged drug).

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

640 Data
Apixaban Apixaban may increase the anticoagulant activities of Desirudin.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Desirudin.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Desirudin.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Desirudin is combined with Deferasirox.
Ursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Cholic Acid.
Glycocholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Taurocholic acid.
Obeticholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Hyodeoxycholic Acid.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Desirudin.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Desirudin.
Obinutuzumab The risk or severity of bleeding and hemorrhage can be increased when Desirudin is combined with Obinutuzumab.
Rivaroxaban Desirudin may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Desirudin is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Desirudin.
Tipranavir The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Desirudin.
Urokinase Urokinase may increase the anticoagulant activities of Desirudin.
Vitamin E Vitamin E may increase the anticoagulant activities of Desirudin.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Desirudin.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Desirudin.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Desirudin.
Quinine The therapeutic efficacy of Desirudin can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Desirudin can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Desirudin.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Desirudin.
Pentoxifylline The therapeutic efficacy of Desirudin can be increased when used in combination with Pentoxifylline.
Pentosan polysulfate Pentosan polysulfate may increase the anticoagulant activities of Desirudin.
Levocarnitine The therapeutic efficacy of Desirudin can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Desirudin.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Desirudin.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Desirudin.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Desirudin.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Desirudin.
Quinestrol Quinestrol may decrease the anticoagulant activities of Desirudin.
Hexestrol Hexestrol may decrease the anticoagulant activities of Desirudin.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Desirudin.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Desirudin.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Desirudin.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Desirudin.
Zeranol Zeranol may decrease the anticoagulant activities of Desirudin.
Equol Equol may decrease the anticoagulant activities of Desirudin.
Methallenestril Methallenestril may decrease the anticoagulant activities of Desirudin.
Epimestrol Epimestrol may decrease the anticoagulant activities of Desirudin.
Moxestrol Moxestrol may decrease the anticoagulant activities of Desirudin.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Desirudin.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Desirudin.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Desirudin.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Desirudin.
Biochanin A Biochanin A may decrease the anticoagulant activities of Desirudin.
Formononetin Formononetin may decrease the anticoagulant activities of Desirudin.
Estriol Estriol may decrease the anticoagulant activities of Desirudin.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Desirudin.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Desirudin.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Desirudin.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Desirudin.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Desirudin.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Desirudin.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Desirudin.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Desirudin.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Desirudin.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Desirudin.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Desirudin.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Desirudin.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Desirudin.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Desirudin.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Desirudin.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Desirudin.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Desirudin.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Desirudin.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Desirudin.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Desirudin.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Desirudin.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Desirudin.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Desirudin.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Desirudin.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Desirudin.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Desirudin.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Desirudin.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Desirudin.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Desirudin.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Desirudin.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Desirudin.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Desirudin.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Desirudin.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Desirudin.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Desirudin.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Desirudin.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Desirudin.
Tiaprofenic acid The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Desirudin.
Etoricoxib The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Desirudin.
Taxifolin The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Desirudin.
Oxyphenbutazone The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Desirudin.

Referensi & Sumber

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Iprivask
    Injection, powder, lyophilized, for solution • 15 mg/100mg • Subcutaneous • US • Approved
  • Iprivask
    Kit • 30 mg/1mL • Subcutaneous • US • Approved
  • Iprivask
    Kit • 30 mg/1mL • Subcutaneous • US • Approved
  • Iprivask
    Kit • 30 mg/1mL • Subcutaneous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul